药物流行病学杂志2024,Vol.33Issue(4) :381-387.DOI:10.12173/j.issn.1005-0698.202306024

注射用生长抑素药物利用评价标准的建立及应用

Establishment and application of drug use evaluation standard of somatostatin for injection

张洁红 蔡慧雅 蔡丽萍 韩一波 张进华
药物流行病学杂志2024,Vol.33Issue(4) :381-387.DOI:10.12173/j.issn.1005-0698.202306024

注射用生长抑素药物利用评价标准的建立及应用

Establishment and application of drug use evaluation standard of somatostatin for injection

张洁红 1蔡慧雅 2蔡丽萍 1韩一波 1张进华3
扫码查看

作者信息

  • 1. 北海市人民医院药剂科(广西北海 536000)
  • 2. 漳州市第二医院药剂科(福建漳州 363199)
  • 3. 福建省妇幼保健院药剂科(福州 350000)
  • 折叠

摘要

目的 建立生长抑素药物利用评价(DUE)标准,评价生长抑素临床使用合理性,为临床合理用药提供参考依据.方法 以注射用生长抑素说明书为基础,参考相关指南和文献建立其DUE标准细则.依据制定的DUE标准细则,对北海市人民医院2021年1-12月使用注射用生长抑素的住院患者病历进行用药合理性评价.结果 共纳入病历407份,用药合理率为94.84%.不合理用药主要表现在适应证(13例,3.19%)、用药频次(7例,1.72%)和药物相互作用(1例,0.25%)等方面.结论 建立的注射用生长抑素DUE标准细则具有较强的可操作性和实用性.该院注射用生长抑素临床应用基本合理,但仍存在一些不合理用药现象,应加强干预.

Abstract

Objective To establish the drug use evaluation(DUE)standard of somatostatin and evaluate the rationality of its clinical use,so as to provide a reference for the rationally clinical application of somatostatin.Methods Based on the specification of somatostatin for injection,related guidelines and literature,DUE standard was established.Evaluate the rationality and standardization of the use of somatostatin for injection at Beihai People's Hospital from January 2021 to December 2021 based on the established DUE standards.Results A total of 407 patients were included,with a medication reasonable rate of 94.84%.The irrational use of drug included unreasonable indications(13 cases,3.19%),unreasonable drug use frequency(7 cases,1.72%),and unreasonable drug interactions(1 case,0.25%).Conclusion The somatostatin for injection DUE standard established is feasible and practical.The clinical application of somatostatin for injection in this hospital is basically reasonable,but there are still some irrational use of somatostatin,which should be strengthened for intervention.

关键词

注射用生长抑素/药物利用评价标准/合理用药

Key words

Somatostatin for injection/Drug use evaluation standard/Rational drug use

引用本文复制引用

出版年

2024
药物流行病学杂志
中国药学会 武汉医药(集团)股份有限公司

药物流行病学杂志

CSTPCD
影响因子:0.746
ISSN:1005-0698
参考文献量17
段落导航相关论文